150 related articles for article (PubMed ID: 34863972)
1. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H
J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972
[TBL] [Abstract][Full Text] [Related]
2. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling.
Zeng X; Zhang J; Yu J; Wu X; Chen Y; Wu J; Yang X; Wang J; Cao G
Adv Clin Exp Med; 2022 May; 31(5):499-509. PubMed ID: 35148573
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Schreiber S; Yamamoto K; Muniz R; Iwura T
Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
BioDrugs; 2020 Jun; 34(3):381-393. PubMed ID: 32078145
[TBL] [Abstract][Full Text] [Related]
7. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.
Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
Clin Rheumatol; 2022 Mar; 41(3):731-739. PubMed ID: 34709497
[TBL] [Abstract][Full Text] [Related]
9. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®).
Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T
Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661
[TBL] [Abstract][Full Text] [Related]
11. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Jiang Y; Arora T; Klakamp S; Davis J; Chandrasekher YA; Young G; Du Y; Yu B; Miller KJ
Drugs R D; 2023 Dec; 23(4):377-395. PubMed ID: 37632627
[TBL] [Abstract][Full Text] [Related]
13. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
Liu J; Eris T; Li C; Cao S; Kuhns S
BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
[TBL] [Abstract][Full Text] [Related]
16. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
Füssl F; Millán-Martín S; Bones J; Carillo S
J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
18. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
Coghlan J; He H; Schwendeman AS
J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the Physicochemical and Biological Stability of the Adalimumab Biosimilar CT-P17.
Shin YK; Han WY; Kim SJ; Kim KW; Roh JW; Lee JB; Oh JS; Astier A
Adv Ther; 2021 Nov; 38(11):5609-5622. PubMed ID: 34618346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
